Study Type . Phase 3. Figure 1. An overview of the pivotal clinical trial program for aripiprazole in MDD is provided in Table 1. CADTH is not responsible for the quality, currency, propriety, accuracy, or reasonableness of any statements, information, or conclusions contained in the source documentation. Patients in this phase were randomized to receive adjunctive aripiprazole patients or placebo patients, and were followed for six weeks. Good luck on your decision. This med helped but affected my sexual health.
These questions, as well as the long-term use of these agents in depression, await further study. This biases the experimental group toward patients who might respond, and makes the results look better. I go to the doctors sooon. Talk with your doctor and family members or friends about deciding to join a study. Effects of adjunctive aripiprazole on sexual functioning in patients with major depressive disorder and an inadequate response to standard antidepressant monotherapy: a post hoc analysis of 3 randomized, double-blind, placebo-controlled studies. Diagnosis and definition of treatment-resistant depression.
Major depressive disorder MDD is a disabling psychiatric condition for which effective treatment remains an outstanding need. Antidepressants are currently the mainstay of treatment for depression; however, almost two-thirds of patients will fail to achieve remission with initial treatment. As a result, a range of augmentation and combination strategies have been used in order to improve outcomes for patients. Despite the popularity of these approaches, limited data from double-blind, randomized, placebo-controlled studies are available to allow clinicians to determine which are the most effective augmentation options or which patients are most likely to respond to which options. Recently, evidence has shown that adjunctive therapy with atypical antipsychotics has the potential for beneficial antidepressant effects in the absence of psychotic symptoms. In particular, aripiprazole has shown efficacy as an augmentation option with standard antidepressant therapy in two, large, randomized, double-blind studies.